Structure-property relationships in ionically substituted bioactive glasses.

一个理念：与其试图在体外重建活组织的复杂性，不如制定合成材料，在与细胞相互作用的同时提供机械完整性，以解锁人体固有的自我修复能力。在托勒的领导下，瑞尔森大学的临床材料小组（CMG）正在设计具有离子结合特性的玻璃基材料，以实现这一理念。该项目将以托勒实验室现有的已发表（156篇同行评议论文）和专利研究（共6篇，其中2篇在相关领域）为基础，招收学生实现四个目标：该计划将扩大对可量化的特定离子掺杂剂对离子玻璃和由它们制造的胶凝材料的物理、机械和体外生物特性的基本理解。该程序将有三个流：1。玻璃和玻璃聚烯酸水泥（GPCs）的合成，其配方具有足够的粘性以承受载荷。2. 溶胶-凝胶电纺丝法将镓离子掺入玻璃。3. 可吸收GPC的研制。b .激励下一代。将为学术、工业和监管行业培训高素质人才（HQP）。他们的技能将通过托勒在加拿大各地的学术、临床和工业合作伙伴的实习来磨练。c .确认研发投资的价值。通过该计划取得的进步将产生用于商业开发的知识产权。这项工作将吸引加拿大初创企业，中小型企业（SME）和跨国企业。Towler拥有授权技术（Opus-Fil+, DS&D，英国）和衍生技术（Crescent Ops，伦敦，英国）。d .提高研究的可见度。Towler将继续在文献中广泛发表，至少保持他现有的速度（每年约15篇论文），并确保HQP在领先的科学会议上传播他们的工作。在加拿大的前五年（2013-2018），托勒从NSERC和CIHR获得了260多万加元的资助，培养了8名博士和4名MASc学生，并指导了4份pdf文件；该小组目前有11名研究生和3个pdf文件；所有项目均由联邦拨款资助，男女比例为50:50。新的HQP将从材料、生物和工程领域招聘；任务是在对加拿大有战略意义的领域对他们进行培训。发现成果可以通过未来的NSERC I2I或合作研究与开发（CRD）或NSERC/CIHR合作健康研究项目（CHRP）赠款加以利用，并且通过后续的认证活动，可以改进骨科手术，从而缩短住院时间并降低医疗成本。

A philosophy: rather than attempting to recreate the complexity of living tissues ex vivo, synthetic materials can be formulated that offer mechanical integrity whilst interacting with cells to unlock the body's inherent ability to self-repair. The Clinical Materials Group (CMG) at Ryerson University, under the leadership of Towler, is designing glass-based materials with properties tailored by ionic incorporation in order to engage this philosophy. The program will build on existing published (156 peer-reviewed papers) and patented (six in total; two in the relevant space) research in Towler's laboratory by recruiting students to fulfil four objectives: A.Advance knowledge. The program will expand the fundamental understanding of the role that specific ionic dopants, in quantifiable amounts, have on the physical, mechanical and in-vitro biological properties of ionomeric glasses and cementitious materials manufactured from them. The program will have three streams: 1. Synthesis of glasses and glass polyalkenoate cements (GPCs) formulated to be sufficiently viscous for load bearing. 2. Incorporation of Gallium ions into glasses by sol-gel electro-spinning. 3. Development of a resorbable GPC. B.Inspire the next generation. Highly qualified personnel (HQP) will be trained for the academic, industrial and regulatory industries. Their skills will be honed by placements with Towler's academic, clinical and industrial collaborators across Canada. C.Confirm the value of R&D investment. Advancements made through the program will result in IP for commercial exploitation. The work will interest Canadian start-ups, small to medium enterprises (SME) and multinational industry. Towler has both licensed (Opus-Fil+, DS&D, UK) and spun-off (Crescent Ops, London, UK) technology. D.Increase visibility of research. Towler will continue to publish extensively in the literature, at the least maintaining his existing rate (~15 papers, annually) and ensuring HQP disseminate their work at leading scientific conferences. In his first five years in Canada (2013-2018), Towler secured over C$2.6m from NSERC and CIHR to graduate eight PhD and four MASc students and mentor four PDFs; the group currently has 11 graduate students and three PDFs; all funded by federal grants with a 50:50 gender balance between men and women. New HQP will be recruited from the materials, biology and engineering fields; the remit being to train them in areas of strategic interest to Canada.  Discovery deliverables may be exploited through future NSERC I2I or Collaborative Research & Development (CRD) or NSERC/CIHR Collaborative Health Research Project (CHRP) grants and, with follow-on accreditation activities, could improve orthopedic procedures leading to shorter hospital stays and reduced healthcare costs.